Ulm, Germany

Juergen Reess

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Neurosearch A/s. Active years: 2012.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Juergen Reess: Innovator in Diabetes Treatment

Introduction

Juergen Reess is a notable inventor based in Ulm, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of type 2 diabetes. His innovative approach has led to the development of a unique patent that addresses a critical health issue affecting millions worldwide.

Latest Patents

Juergen Reess holds a patent for the treatment of type 2 diabetes. The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of diabetic patients. This patent highlights his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Throughout his career, Juergen has been associated with Neurosearch A/S, where he has worked alongside talented professionals in the field. His dedication to research and innovation has positioned him as a key figure in the development of new therapeutic solutions.

Collaborations

Juergen has collaborated with esteemed colleagues such as Klaus Dugi and Andreas Raschig. These partnerships have fostered an environment of creativity and innovation, leading to groundbreaking advancements in diabetes treatment.

Conclusion

Juergen Reess is a pioneering inventor whose work in diabetes treatment exemplifies the impact of innovation in healthcare. His contributions continue to inspire future advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…